Drug delivery specialist Aptar Pharma has announced a strategic three-year research collaboration with Macquarie University in Australia, aimed at optimizing…
Read More
Novo Secures $1.4bn Partnership With Orbis Medicines to Bolster Cardiometabolic Pipeline Through AI-Driven Macrocycle Therapeutics
In a strategic move to fortify its cardiovascular and metabolic disease pipeline following a sequence of high-profile clinical and commercial…
Read More
Eli Lilly and Partner QurCan Therapeutics Form Strategic Alliance to Advance Next-Generation Genetic Medicines for Nervous System Disorders
The landscape of genetic medicine took a significant stride forward as pharmaceutical giant Eli Lilly and Company joined forces with…
Read More
BeOne Medicines Invests $300 Million to Expand Hopewell, New Jersey Manufacturing and Research Operations, Pushing Total US Investment Past $1 Billion
BeOne Medicines is significantly bolstering its presence in the United States with a substantial $300 million investment earmarked for the…
Read More
Fungal gene editing world-first points to promising cancer medicines
A groundbreaking development from the University of Pennsylvania (PA, USA) has introduced a sophisticated gene-editing platform, fPE7max, specifically optimized for…
Read More
Parabilis Medicines Aims for $475 Million Nasdaq IPO to Advance Lead Cancer Asset Zolucatetide
Parabilis Medicines, a promising biotechnology firm, is strategically positioning itself for a significant public market debut, announcing its intention to…
Read More
Parabilis Medicines Aims for $475 Million Nasdaq IPO to Fund Pivotal Desmoid Tumour Trial and Pipeline Expansion
Parabilis Medicines, a biopharmaceutical company forging innovative therapeutic pathways, is charting a course for public market debut with a proposed…
Read More
Eli Lilly and Ascidian Therapeutics Forge Strategic Alliance to Pioneer Novel Genetic Medicines for Kidney Diseases
Eli Lilly and Company, a global pharmaceutical leader, has significantly bolstered its commitment to the cutting-edge field of genetic medicines…
Read More
Revolution Medicines’ Daraxonrasib Achieves Landmark Survival Extension in Pancreatic Cancer, Heralding New Era of Targeted Therapy
The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer. The 2026…
Read More
Regeneron Pharmaceuticals and Parabilis Medicines Forge Landmark $2.32 Billion Collaboration to Pioneer a New Era of Intracellular Therapies
Regeneron Pharmaceuticals has announced a monumental research collaboration with Parabilis Medicines, a deal valued at an impressive $2.32 billion. This…
Read More
